Patent Application
20090068678
(1) Field of the Invention
The present invention relates to methods for identifying modulators of NOAH10. The methods are particularly useful for identifying analytes that antagonize NOAH10's effect on processing of amyloid precursor protein to Aβ peptide and thus useful for identifying analytes that can be used for treating Alzheimer disease.
(2) Description of Related Art
Alzheimer's disease is a common, chronic neurodegenerative disease, characterized by a progressive loss of memory and sometimes-severe behavioral abnormalities, as well as an impairment of other cognitive functions that often leads to dementia and death. It ranks as the fourth leading cause of death in industrialized societies after heart disease, cancer, and stroke. The incidence of Alzheimer's disease is high, with an estimated 2.5 to 4 million patients affected in the United States and perhaps 17 to 25 million worldwide. Moreover, the number of sufferers is expected to grow as the population ages.
A characteristic feature of Alzheimer's disease is the presence of large numbers of insoluble deposits, known as amyloid plaques, in the brains of those affected. Autopsies have shown that amyloid plaques are found in the brains of virtually all Alzheimer's patients and that the degree of amyloid plaque deposition correlates with the degree of dementia (Cummings and Cotman, Lancet 326: 1524-1587 (1995)). While some opinion holds that amyloid plaques are a late stage by-product of the disease process, the consensus view is that amyloid plaques and/or soluble aggregates of amyloid peptides are more likely to be intimately, and perhaps causally, involved in Alzheimer's disease.
A variety of experimental evidence supports this view. For example, amyloid β (Aβ) peptide, a primary component of amyloid plaques, is toxic to neurons in culture and transgenic mice that overproduce Aβ peptide in their brains show significant deposition of Aβ into amyloid plaques as well as significant neuronal toxicity (Yankner, Science 250: 279-282 (1990); Mattson et al., J. Neurosci. 12: 379-389 (1992); Games et al., Nature 373: 523-527 (1995); LaFerla et al., Nature Genetics 9: 21-29 (1995)). Mutations in the APP gene, leading to elevated Aβ production, have been linked to heritable forms of Alzheimer's disease (Goate et al., Nature 349:704-706 (1991); Chartier-Harlan et al., Nature 353:844-846 (1991); Murrel et al., Science 254: 97-99 (1991); Mullan et al., Nature Genetics 1: 345-347 (1992)). Presenilin-1 (PS1) and presenilin-2 (PS2) related familial early-onset Alzheimer's disease (FAD) shows disproportionately increased production of Aβ1-42, the 42 amino acid isoform of Aβ, as opposed to Aβ1-40, the 40 amino acid isoform (Scheuner et al, Nature Medicine 2: 864-870 (1996)). The longer isoform of Aβ is more prone to aggregation than the shorter isoform (Jarrett et al, Biochemistry 32:4693-4697 (1993). Injection of the insoluble, fibrillar form of Aβ into monkey brains results in the development of pathology (neuronal destruction, tau phosphorylation, microglial proliferation) that closely mimics Alzheimer's disease in humans (Geula et al., Nature Medicine 4:827-831 (1998). See, Selkoe, J. Neuropathol. Exp. Neurol. 53: 438-447 (1994) for a review of the evidence that amyloid plaques have a central role in Alzheimer's disease.
Aβ peptide, a 39-43 amino acid peptide derived by proteolytic cleavage of the amyloid precursor protein (APP), is the major component of amyloid plaques (Glenner and Wong, Biochem. Biophys. Res. Comm. 120: 885-890 (1984)). APP is actually a family of polypeptides produced by alternative splicing from a single gene. Major forms of APP are known as APP695, APP751, and APP770, with the subscripts referring to the number of amino acids in each splice variant (Ponte et al., Nature 331: 525-527 (1988); Tanzi et al., Nature 331: 528-530 (1988); Kitaguchi et al., Nature 331: 530-532(1988)). APP is a ubiquitous membrane-spanning (type 1) glycoprotein that undergoes proteolytic cleavage by at least two pathways (Selkoe, Trends Cell Biol. 8: 447-453 (1998)). In one pathway, cleavage by an enzyme known as β-secretase occurs while APP is still in the trans-Golgi secretory compartment (Kuentzel et al., Biochem. J. 295:367-378 (1993)). This cleavage by α-secretase occurs within the Aβ peptide portion of APP, thus precluding the formation of Aβ peptide. In an alternative proteolytic pathway, cleavage of the Met596-Asp597 bond (numbered according to the 695 amino acid protein) by an enzyme known as β-secretase occurs. This cleavage by β-secretase generates the N-terminus of Aβ peptide. The C-terminus is formed by cleavage by a second enzyme known as γ-secretase. The C-terminus is actually a heterogeneous collection of cleavage sites rather than a single site since γ-secretase activity occurs over a short stretch of APP amino acids rather than at a single peptide bond. Peptides of 40 or 42 amino acids in length (Aβ1-40 and Aβ1-42, respectively) predominate among the C-termini generated by γ-secretase. Aβ1-42 peptide is more prone to aggregation than Aβ1-40 peptide, the major secreted species (Jarrett et al., Biochemistry 32: 4693-4697 91993); Kuo et al., J. Biol. Chem. 271: 4077-4081 (1996)), and its production is closely associated with the development of Alzheimer's disease (Sinha and Lieberburg, Proc. Natl. Acad. Sci. USA 96: 11049-11053 (1999)). The bond cleaved by γ-secretase appears to be situated within the transmembrane domain of APP. For a review that discusses APP and its processing, see Selkoe, Trends Cell. Biol. 8: 447-453 (1998).
While abundant evidence suggests that extracellular accumulation and deposition of Aβ peptide is a central event in the etiology of Alzheimer's disease, recent studies have also proposed that increased intracellular accumulation of Aβ peptide or amyloid containing C-terminal fragments may play a role in the pathophysiology of Alzheimer's disease. For example, over-expression of APP harboring mutations which cause familial Alzheimer's disease results in the increased intracellular accumulation of C99, the carboxy-terminal 99 amino acids of APP containing Aβ peptide, in neuronal cultures and Aβ42 in HEK 293 cells in neuronal cultures and Aβ42 peptide in HEK 293 cells. Moreover, evidence suggests that intra- and extracellular Aβ peptide are formed in distinct cellular pools in hippocampal neurons and that a common feature associated with two types of familial Alzheimer's disease mutations in APP (“Swedish” and “London”) is an increased intracellular accumulation of Aβ42 peptide. Thus, based on these studies and earlier reports implicating extracellular Aβ peptide accumulation in Alzheimer's disease pathology, it appears that altered APP catabolism may be involved in disease progression.
Much interest has focused on the possibility of inhibiting the development of amyloid plaques as a means of preventing or ameliorating the symptoms of Alzheimer's disease. To that end, a promising strategy is to inhibit the activity of β- and γ-secretase, the two enzymes that together are responsible for producing Aβ. This strategy is attractive because, if the formation of amyloid plaques is a result of the deposition of Aβ is a cause of Alzheimer's disease, inhibiting the activity of one or both of the two secretases would intervene in the disease process at an early stage, before late-stage events such as inflammation or apoptosis occur. Such early stage intervention is expected to be particularly beneficial (see, for example, Citron, Molecular Medicine Today 6:392-397 (2000)).
To that end, various assays have been developed that are directed to the identification of substances that may interfere with the production of Aβ peptide or its deposition into amyloid plaques. U.S. Pat. No. 5,441,870 is directed to methods of monitoring the processing of APP by detecting the production of amino terminal fragments of APP. U.S. Pat. No. 5,605,811 is directed to methods of identifying inhibitors of the production of amino terminal fragments of APP. U.S. Pat. No. 5,593,846 is directed to methods of detecting soluble Aβ by the use of binding substances such as antibodies. US Published Patent Application No. US20030200555 describes using amyloid precursor proteins with modified β-secretase cleavage sites to monitor beta-secretase activity. Esler et al., Nature Biotechnology 15: 258-263 (1997) described an assay that monitored the deposition of Aβ peptide from solution onto a synthetic analogue of an amyloid plaque. The assay was suitable for identifying substances that could inhibit the deposition of Aβ peptide. However, this assay is not suitable for identifying substances, such as inhibitors of β- or γ-secretase, that would prevent the formation of Aβ peptide.
Various groups have cloned and sequenced cDNA encoding a protein believed to be β-secretase (Vassar et al., Science 286: 735-741 (1999); Hussain et al., Mol. Cell. Neurosci. 14: 419-427 (1999); Yan et al., Nature 402: 533-537 (1999); Sinha et al., Nature 402: 537-540 (1999); Lin et al., Proc. Natl. Acad. Sci. USA 97: 1456-1460 (2000)). U.S. Pat. Nos. 6,828,117 and 6,737,510 disclose a β-secretase, which the inventors call aspartyl protease 2 (Asp2), variant Asp-2(a) and variant Asp-2(b), respectively, and U.S. Pat. No. 6,545,127 discloses a catalytically active enzyme known as memapsin. Hong et al., Science 290: 150-153 (2000) determined the crystal structure of the protease domain of human β-secretase complexed with an eight-residue peptide-like inhibitor at 1.9 angstrom resolution. Compared to other human aspartic proteases, the active site of human β-secretase is more open and less hydrophobic, contributing to the broad substrate specificity of human β-secretase (Lin et al., Proc. Natl. Acad. Sci. USA 97: 1456-1460 (2000)).
Ghosh et al., J. Am. Chem. Soc. 122: 3522-3523 (2000) disclosed two inhibitors of β-secretase, OM99-1 and OM99-2, that are modified peptides based on the β-secretase cleavage site of the Swedish mutation of APP (SEVNL/DAEFR, with “/” indicating the site of cleavage). OM99-1 has the structure VNL*AAEF (with “L*A” indicating the uncleavable hydroxyethylene transition-state isostere of the LA peptide bond) and exhibits a Ki towards recombinant β-secretase produced in E. coli of 6.84×10−8 M±2.72×10−9 M. OM99-2 has the structure EVNL*AAEF (with “L*A” indicating the uncleavable hydroxyethylene transition-state isostere of the LA peptide bond) and exhibits a Ki towards recombinant β-secretase produced in E. coli of 9.58×10−9 M±2.86×10−10 M. OM99-1 and OM99-2, as well as related substances, are described in International Patent Publication WO0100665.
Currently, most drug discovery programs for Alzheimer's disease have targeted either aceytlcholinesterase or the secretase proteins directly responsible for APP processing. While acetylcholinesterase inhibitors are marketed drugs for Alzheimer's disease, they have limited efficacy and do not have disease modifying properties. Secretase inhibitors, on the other hand, have been plagued either by mechanism-based toxicity (γ-secretase inhibitors) or by extreme difficulties in identifying small molecule inhibitors with appropriate pharmacokinetic properties to allow them to become drugs (BACE inhibitors). Identifying novel factors involved in APP processing would expand the range of targets for Alzheimer's disease treatments and therapy.
The present invention provides methods for identifying modulators of NOAH10. The methods are particularly useful for identifying analytes that antagonize NOAH10's effect on processing of amyloid precursor protein to Aβ peptide and thus useful for identifying analytes that can be used for treating Alzheimer disease.
Therefore, in one embodiment, the present invention provides a method for screening for analytes that antagonize processing of amyloid precursor protein (APP) to Aβ peptide, comprising providing recombinant cells, which ectopically expresses NOAH10 and the APP; incubating the cells in a culture medium under conditions for expression of the NOAH10 and APP and which contains an analyte; removing the culture medium from the recombinant cells; and determining the amount of at least one processing product of APP selected from the group consisting of sAPPβ and Aβ peptide in the medium wherein a decrease in the amount of the processing product in the medium compared to the amount of the processing product in medium from recombinant cells incubated in medium without the analyte indicates that the analyte is an antagonist of the processing of the APP to Aβ peptide.
In further aspects of the method, the recombinant cells each comprises a first nucleic acid that encodes NOAH10 operably linked to a first heterologous promoter and a second nucleic acid that encodes an APP operably linked to a second heterologous promoter. In preferred aspects of the present invention, the APP is APPNFEV. In preferred aspects, the method includes a control which comprises providing recombinant cells that ectopically express the APP but not the NOAH10.
The present invention further provides a method for screening for analytes that antagonize processing of amyloid precursor protein (APP) to amyloid β (Aβ) peptide, comprising providing recombinant cells, which ectopically express NOAH10 and a recombinant APP comprising APP fused to a transcription factor that when removed from the APP during processing of the APP produces an active transcription factor, and a reporter gene operably linked to a promoter inducible by the transcription factor; incubating the cells in a culture medium under conditions for expression of the NOAH10 and recombinant APP and which contains an analyte; and determining expression of the reporter gene wherein a decrease in expression of the reporter gene compared to expression of the reporter gene in recombinant cells in a culture medium without the analyte indicates that the analyte is an antagonist of the processing of the APP to Aβ peptide.
In further aspects of the method, the recombinant cells each comprise a first nucleic acid that encodes NOAH10 operably linked to a first heterologous promoter, a second nucleic acid that encodes the recombinant APP operably linked to a second heterologous promoter, and a third nucleic acid that encodes a reporter gene operably linked to a promoter responsive to the transcription factor comprising the recombinant APP.
In light of the analytes that can be identified using the above methods, the present invention further provides a method for treating Alzheimer's disease in an individual which comprises providing to the individual an effective amount of an antagonist of NOAH10 activity.
Further still, the present invention provides a method for identifying an individual who has Alzheimer's disease or is at risk of developing Alzheimer's disease comprising obtaining a sample from the individual and measuring the amount of NOAH10 in the sample.
Further still, the present invention provides for the use of an antagonist of NOAH10 for the manufacture of a medicament for the treatment of Alzheimer's disease.
Further still, the present invention provides for the use of an antibody specific for NOAH10 for the manufacture of a medicament for the treatment of Alzheimer's disease.
Further still, the present invention provides a vaccine for preventing and/or treating Alzheimer's disease in a subject, comprising an antibody raised against an antigenic amount of NOAH10 wherein the antibody antagonizes the processing of APP to Aβ peptide.
The term “analyte” refers to a compound, chemical, agent, composition, antibody, peptide, aptamer, nucleic acid, or the like, which can modulate the activity of NOAH10.
The term “NOAH10” refers to “NOGO-like Alzheimer's hereditary factor on chromosome 10,” also known as LRRTM3 (GenBank Accession Number NP—821079), from human, mouse, Macaca fascicularis, or any other mammal. The term further includes mutants, variants, alleles, and polymorphs of NOAH10. Where appropriate, the term further includes fusion proteins comprising all or a portion of the amino acid sequence of NOAH10 fused to the amino acid sequence of a heterologous peptide or polypeptide, for example, hybrid immuoglobulins comprising the amino acid sequence of NOAH10 or NOAH10 without the transmembrane region fused at its C-terminus to the N-terminus of an immunoglobulin constant region amino acid sequence (See, for example, U.S. Pat. No. 5,428,130 and related patents).
The leucine-rich repeat transmembrane neuronal 3 protein (LRRTM3, herein after referred to as NOAH10) is a neuronal associated protein that Applicants have discovered to have a role in processing of amyloid precursor protein (APP) to amyloid β (Aβ) peptide. A defining characteristic of Alzheimer's disease (AD) is the deposition of aggregated plaques containing Aβ peptide in the brains of affected individuals. Applicants' discovery that NOAH10 has a role processing APP to Aβ peptide suggests that NOAH10 has a role in the progression of Alzheimer's disease in an individual. Therefore, in light of Applicants' discovery, identifying molecules which target activity or expression of NOAH10 would be expected to lead to treatments or therapies for Alzheimer's disease. Expression or activity of NOAH10 may also be useful as a diagnostic marker for identifying individuals who have Alzheimer's disease or are at risk of developing Alzheimer's disease.
The deposition of aggregated plaques containing amyloid β (Aβ) peptide in the brains of individuals affected with Alzheimer's disease is believed to involve the sequential cleavage of APP by two secretase-mediated cleavages to produce Aβ peptide. The first cleavage event is catalyzed by a type I transmembrane aspartyl protease known alternately as β-amyloid converting enzyme 1 (BACE1), Asp2 or memapsin (herein “β-secretase”). β-secretase cleavage of APP695 between amino acids 596 and 597, i.e. β-secretase cleavage site, generates a 596 amino acid soluble N-terminal fragment (sAPPβ) and a 99 amino acid C-terminal fragment (C99). Further cleavage of C99 by γ-secretase (a multicomponent membrane complex consisting of at least presenilin, nicastrin, aph1, and pen2) releases the 40 or 42 amino acid Aβ peptide. An alternative, non-amyloidogenic pathway of APP cleavage is catalyzed by α-secretase, which cleaves APP695 to produce a 613 amino acid soluble N-terminal fragment (sAPPα) and an 83 amino acid (C83). While ongoing drug discovery efforts have focused on identifying antagonists of β-secretase and γ-secretase mediated cleavage of APP, the complicated nature of Alzheimer's disease suggests that efficacious treatments and therapies for Alzheimer's disease might comprise other targets for modulating APP processing. NOAH10 of the present invention is another target for which modulators of (in particular, antagonists) are expected to provide efficacious treatments or therapies for Alzheimer's disease, either alone or in combination with one or more other modulators of APP processing, for example, antagonists selected from the group consisting of β-secretase and γ-secretase.
NOAH10 was identified by screening an siRNA library for siRNA that inhibited APP processing. As described in Example 1, a library of about 15,200 siRNA pools, each targeting a single gene, was transfected individually into recombinant cells ectopically expressing a recombinant APP (APPNFEV). APPNFEV has been described in U.S. Pub. Appln. No. 2003/0200555, comprising isoform APP695 and having HA, Myc, and FLAG sequences at amino acid position 289, an optimized β-secretase cleavage site comprising amino acids NFEV, and a K612V mutation. Metabolites of APPNFEV produced during APP β/γ-secretase or α-secretase processing are sAPPβ with NF at the C-terminus, EV40, and EV42 or sAPPα. EV40 and EV42 are unique Aβ40-like and Aβ42-like peptides that contain the glutamic acid and valine substitutions of APPNFEV, while sAPPβ and sAPPα each contain the HA, FLAG, and myc sequences. The fragments, sAPPβ, sAPPα, EV40, and EV42 were detected by an immunodetection method that used antibodies specific for the various APPNFEV metabolites. Expression levels were determined relative to a non-silencing siRNA control. Following the second round of screening, which consisted of about 1600 siRNAs performed in triplicate repeats, an siRNA was identified that targeted an niRNA encoding a polypeptide with structural similarities to the NOGO family of axon guidance genes and that consistently altered processing of APP to sAPPβ, EV40, and EV42. The nucleic acid encoding this polypeptide, herein designated as NOAH10, was found to have sequence identity to the human LRRTM3 (Lauren et al., Genomics 81: 411-421 (2003); GenBank accession number NM—17801 or AY182027).
The nucleic acid sequence encoding human NOAH10 (SEQ ID NO: 1) is shown in
The mRNA encoding NOAH10 was found to be preferentially enriched in regions of the brain subject to Alzheimer's disease pathology (Example 2) and the gene encoding NOAH10 resides within chromosome 10 near chromosome marker D10S1211 (Example 3), a genomic location that has been implicated to encode genes involved in late onset Alzheimer's disease.
Using a SNP analysis of samples from a proprietary AD population (Celera Diagnostics, Almeda, Calif.) versus age, ApoE genotype and gender matched control populations, the NOAH10 gene has been linked with an increased incidence of AD in ApoE4+ carriers (Example 5). This linkage was confirmed in an independent AD association study (Martin et al., J. Med. Genet. 42(10): 787-792 (2005)).
In light of Applicants' discovery, NOAH10, or modified mutants or variants thereof, is useful for identifying analytes which antagonize processing of APP to produce Aβ peptide. These analytes can be used to treat patients afflicted with Alzheimer's disease. NOAH10 can also be used to help diagnose Alzheimer's disease by assessing genetic variability within the locus. NOAH10 can be used alone or in combination with acetylcholinesterase inhibitors, NMDA receptor partial agonists, secretase inhibitors, amyloid-reactive antibodies, growth hormone secretagogues, and other treatments for Alzheimer's disease.
The present invention provides methods for identifying NOAH10 modulators by contacting NOAH10 with a substance that inhibits or stimulates NOAH10 expression and determining whether expression of NOAH10 polypeptide or nucleic acid molecules encoding an NOAH10 are modified. The present invention also provides methods for identifying modulators that antagonize NOAH10's effect on processing APP to Aβ peptide or formation of Aβ-amyloid plaques in tissues where NOAH10 is localized or co-expressed. For example, NOAH10 protein can be expressed in cell lines that also express APP and the effect of the modulator on Aβ production is monitored using standard biochemical assays with Aβ-specific antibodies or by mass spectrophotometric techniques. Inhibitors for NOAH10 are identified by screening for a reduction in the release of Aβ peptide which is dependent on the presence of NOAH10 protein for effect. Both small molecules and larger biomolecules that antagonize NOAH10-mediated processing of APP to Aβ peptide can be identified using such an assay. A method for identifying antagonists of NOAH10's effect on the processing APP to AD peptide includes the following method which is amenable to high throughput screening. In addition, methods disclosed in U.S. Pub. Appln. No. 2003/0200555 can be adapted to use in assays for identifying antagonists of NOAH10 activity.
A mammalian NOAH10 cDNA, encompassing the first through the last predicted codon contiguously, is amplified from brain total RNA with sequence-specific primers by reverse-transcription polymerase chain reaction (RT-PCR). The amplified sequence is cloned into pcDNA3.zeo or other appropriate mammalian expression vector. Fidelity of the sequence and the ability of the plasmid to encode full-length NOAH10 is validated by DNA sequencing of the NOAH10 plasmid (pcDNA_NOAH10).
Commercially available mammalian expression vectors which are suitable for recombinant NOAH10 expression include, but are not limited to, pcDNA3.neo (Invitrogen, Carlsbad, Calif.), pcDNA3.1 (Invitrogen, Carlsbad, Calif.), pcDNA3.1/Myc-His (Invitrogen), pCI-neo (Promega, Madison, Wis.), pLITMUS28, pLITMUS29, pLITMUS38 and pLITMUS39 (New England Biolabs, Beverly, Mass.), pcDNAI, pcDNAIamp (Invitrogen), pcDNA3 (Invitrogen), pMClneo (Stratagene, La Jolla, Calif.), pXT1 (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo (342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), IZD35 (ATCC 37565), pMC1neo (Stratagene), pcDNA3.1, pCR3.1 (Invitrogen, San Diego, Calif.), EBO-pSV2-neo (ATCC 37593), pCI.neo (Promega), pTRE (Clontech, Palo Alto, Calif.), pV1Jneo, pIRESneo (Clontech, Palo Alto, Calif.), pCEP4 (Invitrogen,), pSC11, and pSV2-dhfr (ATCC 37146). The choice of vector will depend upon the cell type in which it is desired to express the NOAH10, as well as on the level of expression desired, co-transfection with expression vectors encoding APPNFEV, and the like.
Cells transfected with a plasmid vector comprising APPNFEV, for example the HEK293 T/APPNFEV cells used to detect NOAH10 activity in the siRNA screening experiment described in Example 1, are used as described in Example 1 with the following modifications. Cells are co-transfected with a plasmid expression vector comprising APPNFEV operably linked to a heterologous promoter and a plasmid expression vector comprising the NOAH10 operably linked to a heterologous promoter. Alternatively, the BEK293T/APPNFEV cells described in Example 1 are transfected with a plasmid expression vector comprising the NOAH10 operably linked to a heterologous promoter. The promoter comprising the plasmid expression vector can be a constitutive promoter or an inducible promoter. Preferably, the assay includes a negative control comprising the expression vector without NOAH10.
After the cells have been transfected, the transfected or cotransfected cells are incubated with an analyte being tested for its' ability to antagonize NOAH10's effect on processing of APP to Aβ peptide. The analyte is assessed for an effect on the NOAH10 transfected or cotransfected cells that is minimal or absent in the negative control cells. In general, the analyte is added to the cell medium the day after the transfection and the cells are incubated for one to 24 hours with the analyte. In particular embodiments, the analyte is serially diluted and each dilution provided to a culture of the transfected or co-transfected cells. After the cells have been incubated with the analyte, the medium is removed from the cells and assayed for secreted sAPPα, sAPPβ, EV40, and EV42 as described in Examples 1 and 5. Briefly, the antibodies specific for each of the metabolites is used to detect the metabolites in the medium. Preferably, the cells are assessed for viability.
Analytes that alter the secretion of EV40, EV42, sAPPα, and/or sAPPβ in the presence of NOAH10 protein are considered to be modulators of NOAH10 and potential therapeutic agents for NOAH10-related diseases. For example, antagonists of NOAH10 are expected to result in a decrease in the amount of secreted EV40, EV42, and sAPPβ in the medium, whereas an agonist might be expected to cause an increase in the amount of secreted EV40, EV42, and sAPPβ in the medium. An antagonist might further result in an increase in the amount of secreted sAPPα in the medium.
Analytes that alter the secretion of one or more of EV40, EV42, sAPPα, or sAPPβ in the presence of NOAH10 protein are considered to be modulators of NOAH10 and potentially useful as therapeutic agents for NOAH10-related diseases. Direct inhibition or modulation of NOAH10 can be confirmed using binding assays using full-length NOAH10, an extracellular or intracellular domain thereof, or a NOAH10 fusion protein comprising the intracellular or extracellular domain coupled to a C-terminal FLAG, or other, epitopes. A cell-free binding assay using full-length NOAH10, an extracellular or intracellular domain thereof, a NOAH10 fusion protein, or membranes containing NOAH10 integrated therein and a labeled-analyte can be performed and the amount of labeled analyte bound to the NOAH10 determined.
The present invention further provides a method for measuring the ability of an analyte to modulate the level of NOAH10 mRNA or protein in a cell. In this method, a cell that expresses NOAH10 is contacted with a candidate compound and the amount of NOAH10 mRNA or protein in the cell is determined. This determination of NOAH10 levels may be made using any of the above-described immunoassays or techniques disclosed herein. The cell can be any NOAH10 expressing cell, such as a cell transfected with an expression vector comprising NOAH10 operably linked to its native promoter or a cell taken from a brain tissue biopsy from a patient.
The present invention further provides a method of determining whether an individual has a NOAH10-associated disorder or a predisposition for a NOAH10-associated disorder. The method includes providing a tissue or serum sample from an individual and measuring the amount of NOAH10 in the tissue sample. The amount of NOAH10 in the sample is then compared to the amount of NOAH10 in a control sample. An alteration in the amount of NOAH10 in the sample relative to the amount of NOAH10 in the control sample indicates the subject has a NOAH10-associated disorder. A control sample is preferably taken from a matched individual, that is, an individual of similar age, sex, or other general condition but who is not suspected of having an NOAH10 related disorder. In another aspect, the control sample may be taken from the subject at a time when the subject is not suspected of having a condition or disorder associated with abnormal expression of NOAH10.
Other methods for identifying inhibitors of NOAH10 can include blocking the interaction between NOAH10 and the enzymes involved in APP processing or trafficking using standard methodologies for analyzing protein-protein interaction such as fluorescence energy transfer or scintillation proximity assay. Surface Plasmon Resonance can be used to identify molecules that physically interact with purified or recombinant NOAH10. As NOAH10 is likely involved in cell adhesion, inhibitors of NOAH10 can be discovered by blocking NOAH10-dependent cell adhesion (created by co-culturing cells expressing NOAH10 with a suitable adherent partner cell line or by monitoring adhesion to specific chemical or biological substrates).
In accordance with yet another embodiment of the present invention, there are provided antibodies having specific affinity for NOAH10 or an epitope thereof. The term “antibodies” is intended to be a generic term which includes polyclonal antibodies, monoclonal antibodies, Fab fragments, single VH chain antibodies such as those derived from a library of camel or llama antibodies or camelized antibodies (Nuttall et al., Curr. Pharm. Biotechnol. 1: 253-263 (2000); Muyldermans, J. Biotechnol. 74: 277-302 (2001)), and recombinant antibodies. The term “recombinant antibodies” is intended to be a generic term which includes single polypeptide chains comprising the polypeptide sequence of a whole heavy chain antibody or only the amino terminal variable domain of the single heavy chain antibody (VH chain polypeptides) and single polypeptide chains comprising the variable light chain domain (VL) linked to the variable heavy chain domain (VH) to provide a single recombinant polypeptide comprising the Fv region of the antibody molecule (scFv polypeptides) (See, Schmiedl et al., J. Immunol. Meth. 242: 101-114 (2000); Schultz et al., Cancer Res. 60: 6663-6669 (2000); Dübel et al., J. Immunol. Meth. 178: 201-209 (1995); and U.S. Pat. No. 6,207,804 to Huston et al.). Construction of recombinant single VH chain or scFv polypeptides which are specific against an analyte can be obtained using currently available molecular techniques such as phage display (de Haard et al., J. Biol. Chem. 274: 18218-18230 (1999); Saviranta et al., Bioconjugate 9: 725-735 (1999); de Greeff et al., Infect. Immun. 68: 3949-3955 (2000)) or polypeptide synthesis. In further embodiments, the recombinant antibodies include modifications such as polypeptides having particular amino acid residues, ligands or labels, including, but not limited to, horseradish peroxidase, alkaline phosphatase, fluors and the like. Still further embodiments include fusion polypeptides which comprise the above polypeptides fused to a second polypeptide, such as a polypeptide comprising protein A or G.
The antibodies specific for NOAH10 can be produced by methods known in the art. For example, see the methods for producing polyclonal and monoclonal antibodies described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1988). NOAH10 or fragments thereof can be used as immunogens for generating such antibodies. Alternatively, synthetic peptides based on NOAH10 can be prepared (using commercially available synthesizers) and used as immunogens. Amino acid sequences can be analyzed by methods well known in the art to determine whether they encode hydrophobic or hydrophilic domains of the corresponding polypeptide. Altered antibodies such as chimeric, humanized, camelized, CDR-grafted, or bifunctional antibodies can also be produced by methods well known in the art. Such antibodies can also be produced by hybridoma, chemical synthesis or recombinant methods. See, for example, Sambrook et al., supra, and Harlow and Lane, supra. Both anti-peptide and anti-fusion protein antibodies can be used. See, for example, Bahouth et al., Trends Pharmacol. Sci. 12: 338 (1991); Ausubel et al., Current Protocols in Molecular Biology (John Wiley and Sons, N.Y. (1989).
Antibodies so produced can be used for immunoaffinity or affinity chromatography purification of NOAH10 and NOAH10/ligand or analyte complexes. Accordingly, contemplated herein are compositions comprising a carrier and an amount of an antibody having specificity for NOAH10 effective to block naturally occurring NOAH10 from binding its ligand or for effecting the processing of APP to Aβ peptide.
Therefore, in another aspect, the present invention further provides pharmaceutical compositions that antagonize NOAH10's effect on processing of APP to Aβ peptide. Such compositions include a NOAH10 nucleic acid, a NOAH10 peptide, a fusion protein comprising NOAH10 or fragment thereof coupled to a heterologous peptide or protein or fragment thereof, an antibody specific for NOAH10, a nucleic acid or protein aptamer, an siRNA inhibitor to NOAH10 mRNA and an analyte that is a NOAH10 antagonist, or combinations thereof, and a pharmaceutically acceptable carrier or diluent.
In a still further aspect, the present invention provides a kit for in vitro diagnosis of disease by detection of NOAH10 in a biological sample from a patient. A kit for detecting NOAH10 preferably includes a primary antibody capable of binding to NOAH10 and a secondary antibody conjugated to a signal-producing label, the secondary antibody being capable of binding an epitope different from, i.e., spaced from, that to which the primary antibody binds. Such antibodies can be prepared by methods well-known in the art. This kit is most suitable for carrying out a two-antibody sandwich immunoassay, e.g., two-antibody sandwich ELISA.
Using derivatives of NOAH10 protein or cDNA, dominant negative forms of NOAH10 that could interfere with NOAH10-mediated APP processing to Aβ release can be identified. These derivatives could be used in gene therapy strategies or as protein-based therapies to block NOAH10 activity in afflicted patients. NOAH10 can be used to identify endogenous brain proteins that bind to NOAH10 using biochemical purification, genetic interaction, or other techniques common to those skilled in the art. These proteins or their derivatives can subsequently be used to inhibit NOAH10 activity and thus be used to treat Alzheimer's disease. Additionally, polymorphisms in the NOAH10 RNA or in the genomic DNA in and around NOAH10 could be used to diagnose patients at risk for Alzheimer's disease or to identify likely responders in clinical trials.
The following examples are intended to promote a further understanding of the present invention.
NOAH10 was identified in a screen of an siRNA library for modulators of APP processing.
A cell plate was prepared by plating HEK293T/APPNFEV cells to the wells of a 384-well Corning PDL-coated assay plate at a density of about 2,000 cells per well in 40 μL DMEM containing 10% fetal bovine serum (FBS) and antibiotics. The cell plate was incubated overnight at 37° C. in 5% CO2. HEK293T/APPNFEV cells are a sublcone of HEK93T cells stably transformed with the APPNFEV plasmid described in U.S. Published Patent Application No. 20030200555. In brief, APPNFEV encodes human amyloid precursor protein (APP), isoform 1-695, modified at amino acid position 289 by an in-frame insertion of HA, Myc, and FLAG epitope amino acid sequences and at amino acid positions 595, 596, 597, and 598 by substitution of the amino acid sequence NFEV for the endogenous KMDA amino acid sequence, which comprises the β-secretase cleavage site. Thus, β-secretase cleaves the modified cleavage site between amino acids F and E of the modified site NFEV. Maintenance of the plasmid within the sublcone is achieved by culturing the cells in the presence of the antibiotic puromycin.
The next day, the cells in each of the wells of the cell plate were transfected with an siRNA library as follows. Oligofectamine™ (Invitrogen, Inc., Carlsbad, Calif.) was mixed with Opti-MEM® (Invitrogen, Inc., Carlsbad, Calif.) at a ratio of 1 to 40 and 20 μL of the mixture was added to each well of a 384-well plate. To each well of the plate, 980 nL of a particular 10 μM siRNA species was added and the plate incubated for ten minutes at room temperature. Afterwards, five μL of each the siRNA/Oligofectamine™/Opti-MEM® mixtures was added to a corresponding well in the cell plate containing the HEK293/APPNFEV cells. The cell plate was incubated for 24 hours at 37° C. in 5% CO2. Controls were provided which contained non-silencing siRNA or an siRNA that inhibited β-secretase.
On the next day, for each of the wells of the cell plate, the siRNA and Oligofectamine™/Opti-MEM® mixture was removed and replaced with 70 μL DMEM containing 10% FBS and MERCK compound A (See, WO 2003093252, for the preparation of spirocyclic [1,2,5] thiadiazole derivatives as γ-secretase inhibitors for treatment of Alzheimer's disease, Collins et al.), a γ-secretase inhibitor, given at a final concentration equal to its IC50 in cell-based enzyme assays. The cell plate was incubated for 24 hours at 37° C. in 5% CO2.
On the next day, for each of the wells of the cell plate, 64 μL of the medium (conditioned medium) was removed and transferred to four 384-well REMP plates in 22, 22, 10, and 10 μL aliquots for subsequent use in detecting sAPPα, EV42, EV40, sAPPβ using the AlphaScreen™ (PerkinElmer, Wellesley, Mass.) detection technology. Viability of the cells was determined by adding 40 μL 10% AlamarBlue (Serotec, Inc., Raleigh, N.C.) in DMBM containing 10% FBS to each of the wells of the cell plate with the conditioned medium removed. The cell plate was then incubated at 37° C. for two hours. The Acquest™ (Molecular Devices Corporation, Sunnyvale, Calif.) plate reader was used to assay fluorescence intensity (ex. 545 nm, em. 590 nm) as a means to confirm viability of the cells.
Assays for detecting and measuring sAPPβ, EV42, EV40, and sAPPα were detected using antibodies as follows. In general, detection-specific volumes (8 or 0.5 μL) were transferred to a 384-well, white, small-volume detection plate (Greiner Bio-One, Monroe, N.C.). In the case of the smaller volume, 7.5 μL of assay medium was added for a final volume of eight μL per well. One μL of an antibody/donor bead mixture (see below) was dispensed into the solution, and one μL antibody/acceptor bead mixture was added. Plates were incubated in the dark for 24 hours at 4° C. The plates were then read using AlphaQuest™ (PerkinElmer, Wellesley, Mass.) instrumentation. In all protocols, the plating medium was DMEM (Invitrogen, La Jolla, Calif.; Cat. No. 21063-029); 10% FBS, the AlphaScreen™ buffer was 50 mM HEPES, 150 mM NaCl, 0.1% BSA, 0.1% Tween-20, pH 7.5, and the AlphaScreen™ Protein A kit was used.
Anti-NF antibodies and anti-EV antibodies were prepared as taught in U.S. Pub. Appln. 20030200555. β-secretase cleaves between amino acids F and E of the NFEV cleavage site of APPNFEV to produce an sAPPβ peptide with NF at the C-terminus and an EV40 or EV42 peptide with amino acids E and V at the N-terminus. Anti-NF antibodies bind the C-terminal neo-epitope NF at the C-terminus of the sAPPβ peptide produced by β-secretase cleavage of the NFEV sequence of APPNFEV. Anti-EV antibodies bind the N-terminal neo-epitope EV at the N-terminus of EV40 and EV42 produced by β-secretase cleavage of the NFEV sequence of APPNFEV. Anti-Bio-G2-10 and anti-Bio-G2-11 antibodies are available from the Genetics Company, Zurich, Switzerland. Anti-Bio-G2-11 antibodies bind the neo-epitope generated by the γ-secretase cleavage of Aβ or EV peptides at the 42 amino acid position. Anti-Bio-G2-10 antibodies bind the neo-epitope generated by the γ-secretase cleavage of Aβ or EV peptides at the 40 amino acid position. Anti-6E10 antibodies are commercially available from Signet Laboratories, Inc., Dedham, Mass. Anti-6E10 antibodies bind an epitope within amino acids 1 to 17 of the N-terminal region of the Aβ, EV40 and EV42 peptides and also bind sAPPα because the same epitope resides in amino acids 597 to 614 of sAPPα. Bio-M2 anti-FLAG antibodies are available from Sigma-Aldrich, St. Louis, Mo.
Detecting sAPPβ: An AlphaScreen™ assay for detecting sAPβ-NF produced from cleavage of APPNFEV at the β-secreatase cleavage site was performed as follows. Conditioned medium for each well was diluted 32-fold into a final volume of eight μL. As shown in Table 1, biotinylated-M2 anti-FLAG antibody, which binds the FLAG epitope of the APPNFEV, was captured on streptavidin-coated donor beads by incubating a mixture of the antibody and the streptavidin coated beads for one hour at room temperature in AlphaScreen™ buffer. The amount of antibody was adjusted such that the final concentration of antibody in the detection reaction was 3 DM. Anti-NF antibody was similarly captured separately on protein-A acceptor beads in AlphaScreen™ buffer and used at a final concentration of 1 nM (Table 1). The donor and acceptor beads were each used at final concentrations of 20 μg/mL.
Detecting EV42: Conditioned medium for each well was used neat (volume eight μL). As shown in Table 2, anti-Bio-G2-11 antibody was captured on streptavidin-coated donor beads by incubating a mixture of the antibody and the streptavidin coated beads for one hour at room temperature in ALPHASCREEN buffer. The amount of antibody was adjusted such that the final concentration of antibody in the detection reaction was 20 nM. Anti-EV antibody was similarly captured separately on protein-A acceptor beads in AlphaScreen™ buffer and used at a final concentration of 5 nM (Table 2). The donor and acceptor beads were used at a final concentrations of 20 μg/mL.
Detecting EV40: Conditioned medium for each well was diluted four-fold into a final volume eight μL. As shown in Table 3, anti-Bio-G2-10 antibody was captured on streptavidin-coated donor beads by incubating a mixture of the antibody and the streptavidin coated beads for one hour at room temperature in AlphaScreen™ buffer. The amount of antibody was adjusted such that the final concentration of antibody in the detection reaction was 20 nM. Anti-EV antibody was similarly captured separately on protein-A acceptor beads in AlphaScreen™ buffer and used at a final concentration of 5 nM. The donor and acceptor beads were used at a final concentration of 20 μg/mL.
Detecting sAPPα: Conditioned medium for each well was diluted four-fold into a final volume eight μL. As shown in Table 4, Bio-M2 anti-FLAG antibody was captured on streptavidin-coated donor beads by incubating a mixture of the antibody and the streptavidin coated beads for one hour at room temperature in AlphaScreen™ buffer. Anti-6E 10 antibody acceptor beads were obtained from the manufacturer (PerkinElmer, Inc., which makes the beads and conjugates antibody 6E10 to them). Antibody 6E10 (made by Signet Laboratories, Inc.) was used at a final concentration of 30 μg/ml. The donor beads were used at a final concentration of 20 μg/mL.
About 15,200 single replicate pools of siRNAs were tested for modulation of sAPPβ, sAPPα, EV40 and EV42 by the AlphaScreen™ immunodetection method as described above. Based on the profile from this primary screen, 1,622 siRNA were chosen for an additional round of screening in triplicate. An siRNA was defined as “secretase-like” if a significant decrease in sAPPβ, EV40 and EV42 was detected, as well as either no change or an increase in sAPPα.
An siRNA was identified which inhibited an mRNA having a nucleotide sequence encoding a protein which had 100% identity to the nucleotide sequence encoding LRRTM3, the nucleotide sequence of which is set forth in GenBank Accession No. NM—178011 and which was described by Laurén et al., Genomics 81: 411-421 (2003). The amino acid sequence for LRRTM3 is set forth in GenBank Accession No. NP—821079. LRRTM3 was designated herein as NOAH10.
Compared to control non-silencing siRNAs (set to 100%), the NOAH10 siRNA pool significantly decreased EV40 (60.3±4.3%), EV42 (50.1±5.0%) and sAPPβ (42.0±10.0%) while increasing sAPPα (131.3±2.0%). This metabolite profile is similar to that given for a β-secretase control siRNA.
The results are shown schematically in
Because NOAH10 appears to have a role in APP processing to Aβ peptide and, as such, a role in progression of Alzheimer's disease, expression of NOAH10 was assayed in a variety of tissues to determine whether NOAH10 was expressed in the brain.
A proprietary database, the TGI Body Atlas, was used to show that the results of a microarray analysis of the expression of a majority of characterized genes, including NOAH10, in the human genome in a panel of different tissues. NOAH10 mRNA was found to be expressed predominantly in the brain and within corticol structures such as the temporal lobe, entorhinal cortex, and prefrontal cortex, all of which are subject to amyloid Aβ deposition and Alzheimer pathology. The results are summarized in
The results strengthen the conclusion of the Example 1 that NOAH10 has a role in APP processing and, thus, a role in the establishment or progression of Alzheimer's disease.
This example shows that NOAH10 is located within a region of the human genome known to be implicated in late onset of Alzheimer's disease, which further strengthens the conclusion that NOAH10 has a role in the progression of Alzheimer's disease.
Several published population studies have defined genomic locations that influence an individual's propensity to develop Alzheimer's disease. Such studies are able to define particular genomic regions thought to harbor loci that when present or absent, alter an individual's chance of developing Alzheimer's disease. The presence of such loci within or near a gene's genomic location is thought to be a strong indicator of that particular gene's potential influence on disease onset or progression. Myers et al., Science 290: 2304-2305 (2000), and Ertekin-Taner et al., Science 290: 2303-2304 (2000), independently provided evidence suggesting that an Alzheimer's disease locus independent of the APOE genotype is located on chromosome 10 at or close to locus D10S1225. Myers et al., Am. J. Med. Genet. 114: 235-244 (2002) in a further analysis found a linked region on chromosome 10 which spanned approximately 44 centimorgans (cM) from D10S1426 (59 cM) to D1OS2327 (103 cM). To narrow the region, they tested for linkage disequilibrium with several of the stage II microsatellite markers. Of the seven markers tested in family based and case control samples, the only nominally positive association they found was with the 167 bp allele of marker D10S1217.
According to public genome numbering convention, NOAH10 is located on chromosome 10 between base pairs 68,355,819 and 68,529,072 (10q21.3). This corresponds to a genomic location of about 84 cM from the Pterminal end of chromosome 10. This genomic location falls within a region on chromosome 10 near marker D10S1211, which is a marker of significant linkage to late onset Alzheimer's disease as determined by several independent studies as noted above (See, Myers et al. (2000); Ertekin-Taner et al. (2000); Curtis et al., Ann. Hum. Genet. 65: 473-481 (2001). Linkage was also observed in this genomic location using plasma Aβ42 levels as a phenotypic marker suggesting that the loci not only is involved in late onset Alzheimer's disease but may also have a role in or influence APP processing or metabolism (Ertekin-Taner et al. (2000)).
The LRRTM gene family, consisting of LRRTM1, LRRTM2, NOAH10 (LTRRTM3), and LRRTM4, are members of a larger family of leucine rich region (LRR) containing membrane bound receptors with homology to the Drosophila axon guidance gene slit. The LRR often functions in adhesion, in protein-protein interactions, and as a receptor-binding ligand. The therapeutically relevant LRR containing NOGO receptor blocks axonal regeneration and its ligand NOGO has recently been shown to bind BACE1 (β-secretase) and modulate Aβ peptide generation (He et al., Nature Med. 10: 959-965 (2004)). NOAH10 shares sequence and domain homology to the NOGO receptor and was cloned in an approach to identify additional NOGO-like receptors involved in axonal guidance. Taken together, this data suggests the possibility that NOAH10 may be altering Aβ peptide production in a similar manor to the NOGO receptor.
To determine if NOAH10 is a gene linked to Alzheimer's disease and Aβ42 levels on the chromosome 10q region, single nucleotide polymorphisms (SNPs) were examined in four independent case control AD populations owned by Celera Diagnostics, Alameda, Calif. Briefly, two populations of Alzheimer's patients from the United Kingdom and two from the United States of America, comprising approximately 2800 individuals in total, constituted the experimental sample. All AD samples had confirmed Alzheimer's disease (pre-mortem diagnosis) and the controls were age and gender matched. The APOE genotype was known for all patients. Characteristics for the four cohorts of subjects and controls are shown below.
The NOAH10 gene covers approximately 171 kb on chromosome 10q. Examination of the linkage disequilibrium (LD) blocks suggested that NOAH10 spans three blocks. In order to ensure that the promoter and 3′ regions of this gene were included in the analysis, 33 SNPs were examined over a 386 kb region completely covering the three LD blocks that NOAH10 overlaps. The frequency of the allelic forms of these 33 SNPs was first examined in the “discovery” population (UK 2); those which were found to have a p-value <0.1 across all individuals or in any substrata (subjects were stratified by age of onset, gender or APOE genotype) were then genotyped in the remaining three populations. Of the initial 33 SNPs examined, eight reached these criteria and were individually genotyped in the Cardiff, San Diego, and Washington University populations. All SNP assays were performed at Celera Diagnostics, Alameda, Calif. using standard methodology as described by Germer et al., Genome Res. 10(2): 258-266 (2000).
Results of this genetic analysis showed that three SNPs near NOAH10 were associated with increased incidence of Alzheimer's disease in APOE4+ carriers, that is, they had a meta p-value of <0.05 in a case versus control comparison with all subjects treated as one population (Table 6). It is notable that for the two most significant polymorphisms (62097700 and 62254617) the odds ratios were the same across all four populations for each, with 62254617 being “protective” and 62097700 being “causative.”
These results were confirmed in an AD association study where two SNPs in the NOAH10 genomic region were found to have significant association with AD (p<0.05) in APOE4+ carriers in a similar case versus control comparison (Martin et al., J. Med. Genet. 42(10):787-792 (2005)). However, it should be noted that Martin et al. attributed this association to the α-T catenin gene, a nearby gene, rather than NOAH10. Thus, in addition to affecting amnyloid levels via influence on β-secretase activity, as shown by Applicants' in vitro data, the data was indicative that genetic polymorphisms in NOAH10 contribute to the risk of Alzheimer's disease in APOE4+ carriers, a finding further confirmed in a second independent study.
The results of Examples 1-5 have shown that the NOAH10 has a role in the establishment or progression of Alzheimer's disease. The results suggest that analytes that antagonize NOAH10 activity will be useful for the treatment or therapy of Alzheimer's disease. Therefore, there is a need for assays for identifying analytes that antagonize NOAH10 activity, for example, inhibit binding of NOAH10 to its natural ligand or to β-secretase. The following is an assay that can be used to identify analytes that antagonize NOAH10 activity.
BEK293T/APPNFEV cells are transfected with a plasmid encoding the human NOAH10 or a homolog of the human NOAH10, for example, the Macaca fascicularis or mouse NOAH10, using a standard transfection protocols to produce HEK293T/APPNFEV/NOAH10 cells. For example, HEK293T/APPNFEV are plated into a 96-well plate at about 8000 cells per well in 80 μL DMEM containing 10% FBS and antibiotics and the cell plate incubated at 37° C. at 5% CO2 overnight.
On the next day, a mixture of 600 μL Oligofectamine™ and 3000 μL Opti-MEM® is made and incubated at room temperature for five minutes. Next, 23 μL Opti-MEM® is added to each well of a 96-well mixing plate. 50 ng pcDNA_NOAH10 and empty control vector (in 1 μL volume) are added into adjacent wells of the mixing plate in an alternating fashion. The mixing plate is incubated at room temperature for five minutes. Next, 6 μL of the Oligofectamine™ mixture is added to each of the wells of the mixing plate and the mixing plate incubated at room temperature for five minutes. After five minutes, 20 μL of the plasmid/Oligofectamine™ mixture is added to the corresponding well in the plate of BEK293/APPNFEV cells plated in the cell plate and the plates incubated overnight at 37° C. in 5% CO2.
The next day, the medium is removed from each well and replaced with 100 μL DMEM containing 10% FBS. Analytes being assayed for the ability to antagonize NOAH10-mediated activation of Aβ secretion are added to each well individually. The analytes are assessed for an effect on the APP processing to Aβ peptide in NOAH10 transfected cells that is either minimal or absent in cells transfected with the vector-alone as follows. The cells are incubated at 37° C. at 5% CO2 overnight.
The next day, conditioned media is collected the amount of sAPPβ, EV42, EV40, and sAPPα in the conditioned media is determined as described in Example 1. Analytes that effect a decrease in the amounts of sAPPβ, EV42, and EV40 and either an increase or no change in the amount of sAPPα are antagonists of NOAH10. Viability of the cells is determined as in Example 1.
Analytes that alter secretion of EV40, EV42, sAPPa, or sAPPb only, or more, in the presence of NOAH10 are considered to be modulators of NOAH10 and potential therapeutic agents for treating NOAH10-related diseases. The following is an assay that can be used to confirm direct inhibition or modulation of NOAH10.
To confirm direct inhibition or modulation of NOAH10, NOAH10 intracellular or extracellular domains are subcloned into expression plasmid vectors such that a fusion protein with C-terminal FLAG epitopes are encoded. These fusion proteins are purified by affinity chromatography, according to manufacturer's instructions, using an Anti-FLAG M2 agarose resin. NOAH10 fusion proteins are eluted from the Anti-FLAG column by the addition of FLAG peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) (Sigma Aldrich, St. Louis, MO) re-suspended in TBS (50 mM Tris HCl pH 7.4, 150 mM NaCl) to a final concentration of 100 μg/ml. Fractions from the column are collected and concentrations of the fusion proteins determined by A280.
A PD-10 column (Amersham, Boston, Mass.) is used to buffer exchange all eluted fractions containing the NOAH10-fusion proteins and simultaneously remove excess FLAG peptide. The FLAG-NOAH10 fusion proteins are then conjugated to the S series CM5 chip surface (Biacore™ International AB, Uppsala, Sweden) using amine coupling as directed by the manufacturer. A pH scouting protocol is followed to determine the optimal pH conditions for immobilization. Immobilization is conducted at an empirically determined temperature in PBS, pH 7.4, or another similar buffer following a standard Biacore™ immobilization protocol. The reference spot on the CM5 chip (a non-immobilized surface) serves as background. A third spot on the CM5 chip is conjugated with bovine serum albumin in a similar fashion to serve as a specificity control. Interaction of the putative NOAH10 modulating analyte identified in the assay of Example 5 at various concentrations and NOAH10 are analyzed using the compound characterization wizard on the Biacore™ S51. Binding experiments are completed at 30° C. using 50 mM Tris pH 7, 200 uM MnCl2 or MgCl2 (+5% DMSO) or a similar buffer as the running buffer. Prior to each characterization, the instrument is equilibrated three times with assay buffer. Default instructions for characterization are a contact time of 60 seconds, sample injection of 180 seconds and a baseline stabilization of 30 seconds. All solutions are added at a rate of 30 μL/min. Using the BioEvaluation software (Biacore International AB, Uppsala, Sweden), each set of sensorgrams derived from the ligand flowing through the NOAH10-conjugated sensor chip is evaluated and, if binding is observed, an affinity constant determined.
This example describes a method for making polyclonal antibodies specific for the NOAH10 or particular peptide fragments or epitope thereof.
The NOAH10 is produced as described in Example 1 or a peptide fragment comprising a particular amino acid sequence of NAOH10 is synthesized and coupled to a carrier such as BSA or KLH. Antibodies are generated in New Zealand white rabbits over a 10-week period. The NOAH10 or peptide fragment or epitope is emulsified by mixing with an equal volume of Freund's complete adjuvant and injected into three subcutaneous dorsal sites for a total of about 0.1 mg NOAH10 per immunization. A booster containing about 0.1 mg NOAH10 or peptide fragment emulsified in an equal volume of Freund's incomplete adjuvant is administered subcutaneously two weeks later. Animals are bled from the articular artery. The blood is allowed to clot and the serum collected by centrifugation. The serum is stored at 20° C.
For purification, the NOAH10 is immobilized on an activated support. Antisera is passed through the sera column and then washed. Specific antibodies are eluted via a pH gradient, collected, and stored in a borate buffer (0.125M total borate) at −0.25 mg/mL. The anti-NOAH10 antibody titers are determined using ELISA methodology with free cS1P5 receptor bound in solid phase (1 pg/well). Detection is obtained using biotinylated anti-rabbit IgG, HRP-SA conjugate, and ABTS.
This example describes a method for making monoclonal antibodies specific for the NOAH10.
BALB/c mice are immunized with an initial injection of about 1 μg of purified NOAH10 per mouse mixed 1:1 with Freund's complete adjuvant. After two weeks, a booster injection of about 1 μg of the antigen is injected into each mouse intravenously without adjuvant. Three days after the booster injection serum from each of the mice is checked for antibodies specific for the NOAH10.
The spleens are removed from mice positive for antibodies specific for the NOAH10 and washed three times with serum-free DMEM and placed in a sterile Petri dish containing about 20 mL of DMEM containing 20% fetal bovine serum, 1 mM pyruvate, 100 units penicillin, and 100 units streptomycin. The cells are released by perfusion with a 23 gauge needle. Afterwards, the cells are pelleted by low-speed centrifugation and the cell pellet is re-suspended in 5 mL 0.17 M ammonium chloride and placed on ice for several minutes. Then 5 mL of 20% bovine fetal serum is added and the cells pelleted by low-speed centrifugation. The cells are then re-suspended in 10 mL DMEM and mixed with mid-log phase myeloma cells in serum-free DMEM to give a ratio of 3:1. The cell mixture is pelleted by low-speed centrifugation, the supernatant fraction removed, and the pellet allowed to stand for 5 minutes. Next, over a period of 1 minute, 1 mL of 50% polyethylene glycol (PEG) in 0.01 M HEPES, pH 8.1, at 37° C. is added. After 1 minute incubation at 37° C., 1 mL of DMEM is added for a period of another 1 minute, then a third addition of DMEM is added for a further period of 1 minute. Finally, 10 mL of DMEM is added over a period of 2 minutes. Afterwards, the cells are pelleted by low-speed centrifugation and the pellet re-suspended in DMEM containing 20% fetal bovine serum, 0.016 mM thymidine, 0.1 hypoxantlhine, 0.5 μM aminopterin, and 10% hybridoma cloning factor (HAT medium). The cells are then plated into 96-well plates.
After 3, 5, and 7 days, half the medium in the plates is removed and replaced with fresh HAT medium. After 11 days, the hybridoma cell supernatant is screened by an ELISA assay. In this assay, 96-well plates are coated with the NOAH10. One hundred μL of supernatant from each well is added to a corresponding well on a screening plate and incubated for 1 hour at room temperature. After incubation, each well is washed three times with water and 100 μL of a horseradish peroxide conjugate of goat anti-mouse IgG (H+L), A, M (1:1,500 dilution) is added to each well and incubated for 1 hour at room temperature. Afterwards, the wells are washed three times with water and the substrate OPD/hydrogen peroxide is added and the reaction is allowed to proceed for about 15 minutes at room temperature. Then 100 μL of 1 M HCl is added to stop the reaction and the absorbance of the wells is measured at 490 nm. Cultures that have an absorbance greater than the control wells are removed to two cm2 culture dishes, with the addition of normal mouse spleen cells in HAT medium. After a further three days, the cultures are re-screened as above and those that are positive are cloned by limiting dilution. The cells in each two cm2 culture dish are counted and the cell concentration adjusted to 1×105 cells per mL. The cells are diluted in complete medium and normal mouse spleen cells are added. The cells are plated in 96-well plates for each dilution. After 10 days, the cells are screened for growth. The growth positive wells are screened for antibody production; those testing positive are expanded to 2 cm2 cultures and provided with normal mouse spleen cells. This cloning procedure is repeated until stable antibody producing hybridomas are obtained. The stable hybridomas are progressively expanded to larger culture dishes to provide stocks of the cells.
Production of ascites fluid is performed by injecting intraperitoneally 0.5 mL of pristane into female mice to prime the mice for ascites production. After 10 to 60 days, 4.5×106 cells are injected intraperitoneally into each mouse and ascites fluid is harvested between 7 and 14 days later.
While the present invention is described herein with reference to illustrated embodiments, it should be understood that the invention is not limited hereto. Those having ordinary skill in the art and access to the teachings herein will recognize additional modifications and embodiments within the scope thereof. Therefore, the present invention is limited only by the claims attached herein.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2006/016407 | 4/28/2006 | WO | 00 | 11/5/2007 |
| Number | Date | Country | |
|---|---|---|---|
| 60677193 | May 2005 | US | |
| 60750155 | Dec 2005 | US |
